MA40458A - Méthodes de traitement du cancer du col de l'utérus - Google Patents
Méthodes de traitement du cancer du col de l'utérusInfo
- Publication number
- MA40458A MA40458A MA040458A MA40458A MA40458A MA 40458 A MA40458 A MA 40458A MA 040458 A MA040458 A MA 040458A MA 40458 A MA40458 A MA 40458A MA 40458 A MA40458 A MA 40458A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- cervical cancer
- treating cervical
- cervical tumor
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010008342 Cervix carcinoma Diseases 0.000 title 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title 1
- 201000010881 cervical cancer Diseases 0.000 title 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 abstract 3
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
Abstract
La présente invention concerne le traitement d'une tumeur du col de l'utérus provoquée par une infection à papillomavirus humain (hpv). En particulier, l'invention concerne des méthodes pour améliorer le traitement de tumeurs du col de l'utérus et des méthodes pour le traitement des tumeurs du col de l'utérus provoquée par une infection par le hpv à l'aide d'un polynucléotide codant pour une protéine de fusion e6/e7.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462038134P | 2014-08-15 | 2014-08-15 | |
US201462039270P | 2014-08-19 | 2014-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40458A true MA40458A (fr) | 2016-02-18 |
Family
ID=55303926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040458A MA40458A (fr) | 2014-08-15 | 2015-08-14 | Méthodes de traitement du cancer du col de l'utérus |
Country Status (11)
Country | Link |
---|---|
US (2) | US11135262B2 (fr) |
EP (1) | EP3193905B1 (fr) |
JP (2) | JP2017525760A (fr) |
KR (1) | KR102523984B1 (fr) |
CN (1) | CN107073070A (fr) |
AU (1) | AU2015302930C1 (fr) |
BR (1) | BR112017002809A2 (fr) |
CA (1) | CA2957128C (fr) |
MA (1) | MA40458A (fr) |
MX (1) | MX2017002081A (fr) |
WO (1) | WO2016024255A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107073070A (zh) | 2014-08-15 | 2017-08-18 | 格纳西尼有限公司 | 治疗宫颈癌的方法 |
CN106632694B (zh) * | 2017-01-24 | 2021-02-12 | 南京益康生物医药有限公司 | 一种重组蛋白及药物组合物与应用 |
KR102286397B1 (ko) | 2018-02-02 | 2021-08-05 | 주식회사 에스엘백시젠 | 신규 백신 면역보조제 |
KR102222582B1 (ko) * | 2018-02-02 | 2021-03-04 | 주식회사 에스엘백시젠 | 신규 다가 hpv 백신 조성물 |
US11512127B2 (en) * | 2018-02-14 | 2022-11-29 | Viela Bio, Inc. | Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases |
AU2019231654A1 (en) * | 2018-03-06 | 2020-10-01 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
WO2019204634A1 (fr) * | 2018-04-20 | 2019-10-24 | Stc. Unm | Rap1-gtp, rac1-gtp et ligand de tyrosine kinase 3 de type fms (flt3-l) en tant que biomarqueurs pour la détection précoce d'une septicémie |
EP3860316A1 (fr) * | 2020-01-30 | 2021-08-04 | Erbe Elektromedizin GmbH | Plasmas, médias, espèces, systèmes, procédés |
PE20231054A1 (es) * | 2020-04-24 | 2023-07-11 | Genexine Inc | Metodo para tratamiento del cancer cervicouterino |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
EP0279582A3 (fr) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Séquences d'ADN pour diriger des protéines vers les glandes mammaires afin d'être sécrétées efficacement |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
AUPN015794A0 (en) | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
KR100201584B1 (ko) | 1996-07-12 | 1999-06-15 | 손경식 | 사람 파필로마 바이러스 18형 이6 단백질에 대한 인체의 면역성 조절 기능을 갖는 펩타이드 |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
JP2003509035A (ja) | 1999-09-16 | 2003-03-11 | ザイコス インク. | ポリエピトープポリペプチドをコードする核酸 |
ES2284559T3 (es) | 2001-03-23 | 2007-11-16 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Genes y proteinas e6 y e7 modificados del vph utiles como vacuna. |
KR100900249B1 (ko) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | SIVmac239의 면역원성 플라스미드 및 이들을 함유한AIDS DNA 백신 |
KR101145190B1 (ko) * | 2002-10-03 | 2012-05-14 | 와이어쓰 홀딩스 코포레이션 | 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물 |
CN1299769C (zh) | 2005-01-31 | 2007-02-14 | 中国医学科学院肿瘤医院肿瘤研究所 | 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途 |
EP1757615B1 (fr) | 2005-08-24 | 2011-08-24 | Healthbanks Biotech Co., Ltd. | Protéine de fusion pour inhiber le cancer du cervix |
US7732166B2 (en) | 2005-11-15 | 2010-06-08 | Oncohealth Corporation | Detection method for human pappilomavirus (HPV) and its application in cervical cancer |
US8137674B2 (en) | 2006-04-19 | 2012-03-20 | Postech Foundation | Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer |
WO2008046251A1 (fr) | 2006-10-19 | 2008-04-24 | Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. | Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées |
DE102008010954A1 (de) | 2008-02-25 | 2009-08-27 | Cichon, Günter, Prof.Dr. | DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen |
KR101166516B1 (ko) * | 2009-07-02 | 2012-07-20 | 주식회사 바이오드 | 사람 파필로마바이러스 변형체 및 면역 증강제를 포함하는 자궁경부암 예방 또는 치료용 조성물 |
EP2377879A1 (fr) * | 2010-04-14 | 2011-10-19 | Deutsches Krebsforschungszentrum | Protéines de fusion HPV E7 à terminaison N |
CN103180343B (zh) * | 2010-08-13 | 2016-01-20 | 株式会社吉耐森 | 用于预防或治疗宫颈癌的、包含人乳头瘤病毒变形体及免疫增强剂的组合物 |
CN102154325B (zh) * | 2011-01-01 | 2013-08-21 | 上海生物制品研究所有限责任公司 | 针对人乳头瘤状病毒的疫苗及其制法和用途 |
DK2793937T3 (da) | 2011-12-21 | 2019-07-01 | Vaccibody As | Vacciner mod HPV |
CN107073070A (zh) * | 2014-08-15 | 2017-08-18 | 格纳西尼有限公司 | 治疗宫颈癌的方法 |
-
2015
- 2015-08-14 CN CN201580053391.6A patent/CN107073070A/zh active Pending
- 2015-08-14 US US15/503,997 patent/US11135262B2/en active Active
- 2015-08-14 EP EP15832334.5A patent/EP3193905B1/fr active Active
- 2015-08-14 AU AU2015302930A patent/AU2015302930C1/en active Active
- 2015-08-14 CA CA2957128A patent/CA2957128C/fr active Active
- 2015-08-14 KR KR1020177007096A patent/KR102523984B1/ko active IP Right Grant
- 2015-08-14 JP JP2017527988A patent/JP2017525760A/ja active Pending
- 2015-08-14 BR BR112017002809A patent/BR112017002809A2/pt not_active Application Discontinuation
- 2015-08-14 WO PCT/IB2015/056214 patent/WO2016024255A1/fr active Application Filing
- 2015-08-14 MA MA040458A patent/MA40458A/fr unknown
- 2015-08-14 MX MX2017002081A patent/MX2017002081A/es unknown
-
2021
- 2021-04-28 JP JP2021076283A patent/JP7355399B2/ja active Active
- 2021-08-27 US US17/459,460 patent/US20220096589A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11135262B2 (en) | 2021-10-05 |
BR112017002809A2 (pt) | 2017-12-19 |
AU2015302930C1 (en) | 2023-06-01 |
EP3193905A1 (fr) | 2017-07-26 |
EP3193905B1 (fr) | 2024-04-03 |
AU2015302930A1 (en) | 2017-02-23 |
CA2957128A1 (fr) | 2016-02-18 |
US20170304385A1 (en) | 2017-10-26 |
CN107073070A (zh) | 2017-08-18 |
EP3193905A4 (fr) | 2018-05-09 |
WO2016024255A1 (fr) | 2016-02-18 |
JP2021119174A (ja) | 2021-08-12 |
KR102523984B1 (ko) | 2023-04-20 |
KR20170045254A (ko) | 2017-04-26 |
MX2017002081A (es) | 2017-05-23 |
JP2017525760A (ja) | 2017-09-07 |
US20220096589A1 (en) | 2022-03-31 |
AU2015302930B2 (en) | 2020-11-26 |
CA2957128C (fr) | 2023-09-26 |
JP7355399B2 (ja) | 2023-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
MA40458A (fr) | Méthodes de traitement du cancer du col de l'utérus | |
MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
MX2022007522A (es) | Anticuerpos anti-cd27. | |
MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
GB2541571A (en) | Pharmaceutical compositions | |
GEP20217317B (en) | Combination therapy for the treatment of cancer | |
NZ723884A (en) | Methods of treating alzheimer’s disease | |
MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
EP4353320A3 (fr) | Utilisation de plasma sanguin et fractions de plasma sanguin en tant que therapie pour lutter contre la croissance et la progression tumorale | |
MX2017000306A (es) | Metodos para tratar hipotension. | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
MX2023007706A (es) | Nanoparticulas para su uso como vacuna terapeutica. | |
MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
WO2013162981A3 (fr) | Écarteurs d'implants mammaires pour le traitement des infections périprothétiques des implants mammaires | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
GB2546703A (en) | Compounds | |
MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci | |
UA107743C2 (ru) | Способ лечения аденокарциномы |